Henry Meds semaglutide typically refers to obtaining semaglutide through the Henry Meds telehealth platform. Semaglutide is prescription-only in the United States, so any legitimate pathway, including Henry Meds, must include a licensed clinician evaluation and an FDA-registered pharmacy. This article explains the regulatory framework and what to verify before starting.
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist approved by the FDA under several brand names:
- Ozempic: once-weekly injection for adults with type 2 diabetes, with additional approved use for reducing major adverse cardiovascular events.
- Wegovy: once-weekly injection for chronic weight management in adults with obesity or overweight plus a weight-related condition, with a cardiovascular risk reduction indication added in 2024.
- Rybelsus: once-daily oral tablet for adults with type 2 diabetes.
All three are manufactured by Novo Nordisk. Compounded semaglutide is a separate regulatory category not FDA-approved for safety and effectiveness.
What a Telehealth Semaglutide Visit Looks Like
A compliant telehealth semaglutide program generally includes:
- Medical intake. Weight, BMI, medical history, current medications, family history (especially thyroid and pancreatic).
- Clinician consultation. A state-licensed clinician reviews intake, usually by video or secure messaging.
- Eligibility assessment. The clinician applies FDA-approved criteria (for example, BMI thresholds for Wegovy, A1C and diabetes status for Ozempic).
- Prescription. If eligible, the clinician issues a prescription to an FDA-registered pharmacy.
- Follow-up. Scheduled check-ins for dose changes, side effects, and progress tracking.
State medical boards oversee telehealth clinicians the same way they oversee in-person practitioners. The Federation of State Medical Boards maintains state-level telehealth policies.
Branded vs. Compounded Semaglutide
Several telehealth platforms, including some programs during the FDA shortage period, offered compounded semaglutide. This is an important distinction.
| Product | Regulatory Status | Typical Pathway |
|---|---|---|
| Ozempic / Wegovy / Rybelsus | FDA-approved | Licensed prescriber + FDA-registered pharmacy |
| Compounded semaglutide | Not FDA-approved for safety/effectiveness | Prepared by a compounding pharmacy; allowance narrowed after shortage ended |
The FDA has documented adverse events from compounded semaglutide, including dosing errors and use of unapproved salt forms (semaglutide sodium, semaglutide acetate). The agency’s Drug Safety and Availability page publishes current guidance.
Questions to Ask Any Telehealth Platform
- Is the prescribing clinician licensed in my state?
- Which FDA-approved indication applies to me?
- Am I receiving branded Ozempic, Wegovy, or Rybelsus, or compounded semaglutide?
- What is the dispensing pharmacy, and is it FDA-registered?
- How is prior authorization handled if I use insurance?
- What does follow-up look like (cadence, messaging access, lab orders)?
- How do I reach the clinician for side effects or emergencies?
Transparent answers to these questions are the main indicator of a safe platform. Vague or evasive responses are a red flag.
Potential Benefits of Telehealth Access
For eligible patients, telehealth can expand access in meaningful ways:
- Geographic reach to clinicians who focus on metabolic health
- Evening and weekend scheduling
- Integrated tracking tools for weight, glucose, and symptoms
- Reduced stigma or embarrassment for weight-related conversations
Medication also works best alongside structured lifestyle change. Our nutrition guide and treatment overview cover the foundations most clinicians recommend regardless of delivery model.
Side Effects and Monitoring
According to the FDA-approved labels, semaglutide’s common side effects are primarily gastrointestinal:
- Nausea, diarrhea, vomiting, constipation, abdominal pain
- Fatigue and headache
- Injection-site reactions
- Hair shedding at low rates, typically related to rapid weight loss
Serious warnings include pancreatitis, gallbladder disease, severe GI reactions, acute kidney injury from dehydration, diabetic retinopathy complications in patients with a history of retinopathy, and hypoglycemia when combined with insulin or sulfonylureas. A boxed warning addresses thyroid C-cell tumors; semaglutide is contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2.
Your telehealth clinician should monitor weight, GI tolerability, hydration, and, if relevant, A1C levels.
Insurance, Cost, and Continuity
Telehealth platforms vary widely in insurance support. Some accept commercial insurance and file prior authorizations; others are cash-pay. Ask whether the platform can:
- File prior authorization on your behalf
- Provide documentation for appeals
- Coordinate with your primary care clinician
- Transfer care if you move or switch providers
Medical disclaimer: This article is educational only and is not medical advice. Do not start, stop, or change any prescription medication without consulting a licensed clinician.
The Bottom Line
Henry Meds semaglutide, and any other telehealth semaglutide offering, must meet the same regulatory bar as in-person care: licensed clinician, FDA-approved indication, FDA-registered pharmacy, and meaningful follow-up. Clarify whether the product is branded or compounded, confirm clinician licensure, and treat telehealth as a delivery channel, not a regulatory shortcut.
